GreenDot Stocks
Back to screen

Neurocrine Biosciences (NBIX)

Generated: November 7, 2026
Green Dot

Statistics

MetricValue
Last Close$164.67
Blended Price Target176.46
Blended Margin of Safety7.2% Fairly Valued
Rule of 40 (Next)41.8%
Rule of 40 (Current)60.3%
FCF-ROIC24.3%
Sales Growth Next Year17.4%
Sales Growth Current Year36.0%
Sales 3-Year Avg27.5%
IndustryDrug Manufacturers - Specialty & Generic

Analysis

Neurocrine Biosciences is a high-quality commercial biopharmaceutical company with an unusually strong current revenue base and a credible path to extend growth through both lifecycle management and pipeline expansion. Its third quarter of 2026 produced record net product sales above $1.1 billion and record profitability, demonstrating substantial commercial momentum in its marketed portfolio.[1]

The business is not fully insulated from drug-development risk, but its durability is better than that of a typical single-asset biotech. Revenue is largely tied to recurring prescriptions rather than one-time transactions, while the company’s specialty focus, regulatory know-how, and established commercial infrastructure create meaningful advantages. Leadership appears execution-oriented: management is simultaneously scaling the existing franchise and advancing programs across neurology, psychiatry, obesity, immunology, and gene therapy.[1][2]

What the Company Does

Neurocrine discovers, develops, and commercializes medicines for neurological, psychiatric, and endocrine disorders. It makes money primarily by selling approved prescription medicines, supported by internal research and development and selected collaborations.

The current business is centered on three first-in-class medicines, according to management’s latest quarterly commentary.[1] The available search results do not provide a sufficiently detailed, recent segment-percentage breakdown, but the revenue mix is predominantly product sales rather than licensing or project revenue.

Revenue Recurrence & Predictability

Neurocrine’s revenue is primarily transactional at the point of prescription fulfillment, but economically it behaves as recurring revenue because patients often remain on chronic therapies and prescriptions are refilled over time. This makes the base more predictable than one-time product sales, although it remains exposed to discontinuations, payer decisions, treatment adoption, and competitive launches.

A current percentage for recurring or highly predictable revenue is not disclosed in the available materials. Predictability is strongest in the established commercial franchise and weaker in newer indications, where uptake depends on physician awareness, reimbursement, diagnosis rates, and evidence generated after launch.

Revenue Growth Durability

Neurocrine can plausibly sustain above-market growth for several years if its commercial medicines continue expanding within their approved populations and new indications or products reach patients successfully. Management is also broadening the pipeline: recent development activity includes programs in Alzheimer’s disease, obesity, schizophrenia, major depressive disorder, immunology, and Friedreich’s ataxia.[1][2]

The principal growth levers are greater penetration of existing markets, additional approved indications, geographic or patient access expansion, and pipeline launches. Structural demand is supported by substantial unmet need in neurological and psychiatric disorders, but growth will face normal pharmaceutical headwinds: finite addressable populations, payer scrutiny, generic or branded competition, and clinical-development setbacks.

Economic Moat

The moat rests primarily on intangible assets and execution capabilities rather than network effects or manufacturing cost leadership. Approved medicines, clinical data, regulatory exclusivity, physician familiarity, and specialized commercialization create protection that competitors must overcome through superior efficacy, safety, convenience, or pricing.

Neurocrine also benefits from a focused specialty-commercial infrastructure and experience navigating difficult central-nervous-system markets. The moat is potentially widening as the company adds indications and advances a broader pipeline, but it is not permanent: patent expiry, competing mechanisms, safety findings, and failed trials can erode product-specific advantages quickly.

Management & Leadership

Neurocrine is not founder-led. Kyle Gano is the chief executive officer, and the latest available company materials identify him as leading the 2026 operating and development agenda.[1][2] The recent record of commercial execution and expanding clinical activity supports a favorable view of management’s operating discipline.

A current, reliable insider-ownership figure and a complete recent capital-allocation summary are not available in the search results. The clearest recent allocation priority is continued investment in research and development, including six planned phase-one starts and five new phase-two starts during 2026.[1]

Key Risks

Clinical risk remains substantial. Several future growth drivers depend on trials producing positive efficacy and safety results, obtaining regulatory approval, and demonstrating differentiated value against established therapies. The company’s expanding pipeline improves optionality but also increases the number of programs that can consume capital without producing a commercial product.

Commercial concentration is another risk. Even with three marketed medicines, a limited portfolio means unexpected safety issues, reimbursement restrictions, manufacturing disruptions, or stronger competing products could materially affect results. Prescription demand can also be pressured by payer controls and changing treatment guidelines.

Finally, the central-nervous-system and emerging obesity markets are highly competitive and technologically uncertain. New mechanisms may fail clinically, while larger pharmaceutical companies can bring greater resources to late-stage development, promotion, and pricing negotiations. Collaborations, including the gene-therapy program with Voyager Therapeutics, add capability but also introduce execution and partnership-dependence risks.[1][2]

Sources

  1. https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/0000914475-26-000054-index.html
  2. https://www.sec.gov/ix?doc=/Archives/edgar/data/0000914475/000091447526000037/nbix-20260630.htm
  3. https://neurocrine.gcs-web.com/investors/sec-filings
  4. https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/q3-2026xexhibit312.htm
  5. https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/q3-2026xexhibit311.htm
  6. https://www.neurocrine.com/investors/
  7. https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/q2-2026xexhibit32.htm
  8. http://www.finance.yahoo.com/quote/0K6R.L/earnings/0K6R.L-Q3-2026-earnings_call-720213.html
  9. https://www.neurocrine.com/investors/webcasts-presentations/
  10. https://au.investing.com/news/stock-market-news/earnings-call-transcript-neurocrine-beats-q3-2026-estimates-shares-jump-after-hours-93CH-4735685

Featured in GreenDot Stocks Analysis